Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Core Insights - Vor Bio has initiated the first patient dosing in the Phase 3 UPSTREAM SjD trial for telitacicept, targeting primary Sjögren's disease, which currently lacks approved therapies [1][2] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1] - The company is advancing global development programs for major autoimmune indications, including a Phase 3 trial for generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD) [7] Product Information - Telitacicept is a novel investigational recombinant fusion protein that inhibits BAFF and APRIL, two cytokines crucial for B cell survival, thereby reducing autoreactive B cells and autoantibody production [5] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), with additional regulatory filings for SjD and IgA nephropathy (IgAN) underway [6] Clinical Trial Details - The UPSTREAM SjD trial will involve approximately 250 adult patients with active primary Sjögren's disease, evaluating the efficacy and safety of telitacicept compared to placebo [2] - The primary endpoint is the change in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48, with key secondary endpoints assessing systemic disease activity, glandular function, and patient-reported symptoms [2] Disease Context - Sjögren's disease is a chronic autoimmune condition characterized by overactive B cells leading to inflammation and damage to moisture-producing glands, with symptoms including dry eyes, dry mouth, fatigue, and systemic complications [3][4] - The disease is underdiagnosed, with about half of the cases unrecognized, and predominantly affects women [4]